See more : Shankar Lal Rampal Dye-Chem Li (SRD.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Establishment Labs Holdings Inc. (ESTA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Establishment Labs Holdings Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- PT Austindo Nusantara Jaya Tbk (ANJT.JK) Income Statement Analysis – Financial Results
- Celyad Oncology SA (0QFK.L) Income Statement Analysis – Financial Results
- EHAVE, Inc. (EHVVF) Income Statement Analysis – Financial Results
- Oi S.A. (OIBR-C) Income Statement Analysis – Financial Results
- People.cn CO., LTD (603000.SS) Income Statement Analysis – Financial Results
Establishment Labs Holdings Inc. (ESTA)
About Establishment Labs Holdings Inc.
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution. The company sells its products through exclusive distributors and direct sales force in Europe, Latin America, the Asia-Pacific, and internationally. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 165.15M | 161.70M | 126.68M | 84.68M | 89.57M | 61.21M | 34.68M | 19.80M |
| Cost of Revenue | 58.17M | 55.11M | 41.28M | 32.17M | 34.70M | 25.09M | 16.98M | 9.71M |
| Gross Profit | 106.98M | 106.60M | 85.40M | 52.50M | 54.86M | 36.12M | 17.70M | 10.10M |
| Gross Profit Ratio | 64.78% | 65.92% | 67.42% | 62.00% | 61.25% | 59.01% | 51.04% | 50.99% |
| Research & Development | 26.43M | 20.27M | 18.32M | 13.79M | 14.99M | 12.69M | 6.86M | 2.74M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 47.30M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 145.58M | 125.98M | 92.23M | 66.63M | 70.81M | 47.30M | 30.82M | 23.19M |
| Other Expenses | 0.00 | -3.18M | -6.27M | -2.68M | -1.21M | -2.39M | -1.98M | -334.00K |
| Operating Expenses | 172.00M | 146.25M | 110.54M | 80.42M | 85.80M | 59.98M | 37.69M | 25.93M |
| Cost & Expenses | 230.18M | 201.36M | 151.82M | 112.59M | 120.51M | 85.07M | 54.66M | 35.63M |
| Interest Income | 1.02M | 87.00K | 23.00K | 15.00K | 4.00K | 16.00K | 19.00K | 44.00K |
| Interest Expense | 15.39M | 11.76M | 9.06M | 9.37M | 8.70M | 8.81M | 10.42M | 3.41M |
| Depreciation & Amortization | 4.88M | 4.17M | 4.11M | 3.66M | 3.30M | 2.80M | 1.94M | 592.00K |
| EBITDA | -58.31M | -56.90M | -26.54M | -24.93M | -25.51M | -9.27M | -22.43M | -18.02M |
| EBITDA Ratio | -35.31% | -26.44% | -24.78% | -36.11% | -35.89% | -42.86% | -57.68% | -78.44% |
| Operating Income | -65.03M | -39.66M | -25.14M | -27.92M | -30.94M | -23.86M | -19.98M | -15.83M |
| Operating Income Ratio | -39.37% | -24.53% | -19.84% | -32.97% | -34.55% | -38.99% | -57.62% | -79.96% |
| Total Other Income/Expenses | -13.56M | -33.17M | -14.57M | -10.10M | -6.57M | 2.98M | -14.81M | -6.19M |
| Income Before Tax | -78.58M | -72.82M | -39.71M | -38.02M | -37.51M | -20.88M | -34.79M | -22.03M |
| Income Before Tax Ratio | -47.58% | -45.04% | -31.35% | -44.90% | -41.88% | -34.12% | -100.32% | -111.23% |
| Income Tax Expense | -81.00K | 2.39M | 1.43M | 104.00K | 640.00K | 215.00K | 105.00K | 134.00K |
| Net Income | -78.50M | -75.21M | -41.14M | -38.12M | -38.15M | -21.10M | -34.90M | -22.16M |
| Net Income Ratio | -47.53% | -46.51% | -32.47% | -45.02% | -42.59% | -34.47% | -100.62% | -111.91% |
| EPS | -3.07 | -3.08 | -1.72 | -1.63 | -1.86 | -1.22 | -2.33 | -1.20 |
| EPS Diluted | -3.07 | -3.08 | -1.72 | -1.63 | -1.86 | -1.22 | -1.89 | -1.20 |
| Weighted Avg Shares Out | 25.60M | 24.46M | 23.97M | 23.32M | 20.54M | 17.35M | 14.98M | 18.49M |
| Weighted Avg Shares Out (Dil) | 25.60M | 24.46M | 23.97M | 23.32M | 20.54M | 17.35M | 18.49M | 18.49M |
Establishment Labs Holdings Inc. (ESTA) Q3 2024 Earnings Call Transcript
Establishment Labs Holdings Inc. (NASDAQ:ESTA ) Q3 2024 Earnings Call Transcript November 7, 2024 4:30 PM ET Company Participants Rajbir Denhoy - Chief Financial Officer Juan Jose - CEO and Founder Conference Call Participants Allen Gong - JPMorgan Matt Taylor...
Establishment Labs Holdings Inc. (ESTA) Reports Q3 Loss, Misses Revenue Estimates
Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $1.12 per share a year ago.
Establishment Labs Announces $50 Million Registered Direct Offering
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (Nasdaq: ESTA) (the “Company”), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that it has entered into a securities purchase agreement (the...
Establishment Labs Announces Three-Year Mia Femtech Clinical Results at 9th World Symposium on Ergonomic Implants
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced the presentation of three-year clinical results with Mia Femtech™ at the 9th Annual...
Establishment Labs Holdings Inc (ESTA) Stock Price Up 9.25% on Oct 2
Shares of Establishment Labs Holdings Inc (ESTA, Financial) surged 9.25% in mid-day trading on Oct 2. The stock reached an intraday high of $44.42, before settling at $44.31, up from its previous close of $40.56.
Establishment Labs Receives U.S. FDA Approval for Motiva Implants
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced it has received approval from the U.S. Food and Drug Administration (FDA) for...
Establishment Labs Holdings Inc. (ESTA) Reports Q2 Loss, Tops Revenue Estimates
Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.65 per share a year ago.
Establishment Labs to Announce Second Quarter 2024 Financial Results on August 6
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended June 30, 2024, after...
Establishment Labs (ESTA) Surges 7.4%: Is This an Indication of Further Gains?
Establishment Labs (ESTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Establishment Labs Announces Participation in Two Upcoming Investment Conferences
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in two upcoming investment conferences. Juan José Chacón-Quirós, Chief Executive...
Source: https://incomestatements.info
Category: Stock Reports